Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
494 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Depression - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Depression - Pipeline Review, H2 2016', provides an overview of the Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Depression therapeutics and enlists all their major and minor projects - The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Depression Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Depression - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 8 Depression Overview 9 Therapeutics Development 10 Depression - Therapeutics under Development by Companies 12 Depression - Therapeutics under Investigation by Universities/Institutes 20 Depression - Pipeline Products Glance 22 Depression - Products under Development by Companies 26 Depression - Products under Investigation by Universities/Institutes 37 Depression - Companies Involved in Therapeutics Development 39 Depression - Therapeutics Assessment 131 Drug Profiles 151 Depression - Dormant Projects 432 Depression - Discontinued Products 457 Depression - Product Development Milestones 465 Appendix 474
List of Tables
Number of Products under Development for Depression, H2 2016 29 Number of Products under Development for Depression - Comparative Analysis, H2 2016 30 Number of Products under Development by Companies, H2 2016 32 Number of Products under Development by Companies, H2 2016 (Contd..1) 33 Number of Products under Development by Companies, H2 2016 (Contd..2) 34 Number of Products under Development by Companies, H2 2016 (Contd..3) 35 Number of Products under Development by Companies, H2 2016 (Contd..4) 36 Number of Products under Development by Companies, H2 2016 (Contd..5) 37 Number of Products under Development by Companies, H2 2016 (Contd..6) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 40 Comparative Analysis by Late Stage Development, H2 2016 41 Comparative Analysis by Clinical Stage Development, H2 2016 42 Comparative Analysis by Early Stage Development, H2 2016 43 Comparative Analysis by Unknown Stage Development, H2 2016 44 Products under Development by Companies, H2 2016 45 Products under Development by Companies, H2 2016 (Contd..1) 46 Products under Development by Companies, H2 2016 (Contd..2) 47 Products under Development by Companies, H2 2016 (Contd..3) 48 Products under Development by Companies, H2 2016 (Contd..4) 49 Products under Development by Companies, H2 2016 (Contd..5) 50 Products under Development by Companies, H2 2016 (Contd..6) 51 Products under Development by Companies, H2 2016 (Contd..7) 52 Products under Development by Companies, H2 2016 (Contd..8) 53 Products under Development by Companies, H2 2016 (Contd..9) 54 Products under Development by Companies, H2 2016 (Contd..10) 55 Products under Investigation by Universities/Institutes, H2 2016 56 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 57 Depression - Pipeline by AB Science SA, H2 2016 58 Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59 Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 60 Depression - Pipeline by Adamed Sp. z o.o., H2 2016 61 Depression - Pipeline by Addex Therapeutics Ltd, H2 2016 62 Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 63 Depression - Pipeline by Alkermes Plc, H2 2016 64 Depression - Pipeline by Allergan Plc, H2 2016 65 Depression - Pipeline by Alvogen Korea Co., Ltd., H2 2016 66 Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016 67 Depression - Pipeline by Anavex Life Sciences Corp., H2 2016 68 Depression - Pipeline by Angelini Group, H2 2016 69 Depression - Pipeline by Angita B.V., H2 2016 70 Depression - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 71 Depression - Pipeline by AstraZeneca Plc, H2 2016 72 Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 73 Depression - Pipeline by Axsome Therapeutics Inc, H2 2016 74 Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 75 Depression - Pipeline by BioCrea GmbH, H2 2016 76 Depression - Pipeline by Biogen Inc, H2 2016 77 Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 78 Depression - Pipeline by BioLite, Inc., H2 2016 79 Depression - Pipeline by Bionomics Limited, H2 2016 80 Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2016 81 Depression - Pipeline by Bristol-Myers Squibb Company, H2 2016 82 Depression - Pipeline by Calico LLC, H2 2016 83 Depression - Pipeline by Celon Pharma Sp. z o.o., H2 2016 84 Depression - Pipeline by Cerecor Inc., H2 2016 85 Depression - Pipeline by Clera Inc., H2 2016 86 Depression - Pipeline by D-Pharm Ltd., H2 2016 87 Depression - Pipeline by Delpor, Inc., H2 2016 88 Depression - Pipeline by e-Therapeutics Plc, H2 2016 89 Depression - Pipeline by Eisai Co., Ltd., H2 2016 90 Depression - Pipeline by Eli Lilly and Company, H2 2016 91 Depression - Pipeline by Evotec AG, H2 2016 92 Depression - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 93 Depression - Pipeline by GlaxoSmithKline Plc, H2 2016 94 Depression - Pipeline by GliaCure Inc., H2 2016 95 Depression - Pipeline by H. Lundbeck A/S, H2 2016 96 Depression - Pipeline by Heptares Therapeutics Limited, H2 2016 97 Depression - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 98 Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 99 Depression - Pipeline by Impel NeuroPharma, Inc., H2 2016 100 Depression - Pipeline by INSYS Therapeutics, Inc., H2 2016 101 Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 102 Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 103 Depression - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 104 Depression - Pipeline by Johnson & Johnson, H2 2016 105 Depression - Pipeline by KemPharm, Inc., H2 2016 106 Depression - Pipeline by Lead Discovery Center GmbH, H2 2016 107 Depression - Pipeline by Les Laboratoires Servier SAS, H2 2016 108 Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 109 Depression - Pipeline by Luye Pharma Group Ltd., H2 2016 110 Depression - Pipeline by Mapi Pharma Ltd., H2 2016 111 Depression - Pipeline by Mapreg S.A.S., H2 2016 112 Depression - Pipeline by Meta-IQ ApS, H2 2016 113 Depression - Pipeline by Methylation Sciences Inc., H2 2016 114 Depression - Pipeline by miCure Therapeutics Ltd., H2 2016 115 Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 116 Depression - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 117 Depression - Pipeline by Neuralstem, Inc., H2 2016 118 Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2016 119 Depression - Pipeline by NeuroNascent, Inc., H2 2016 120 Depression - Pipeline by NeurOp, Inc, H2 2016 121 Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 122 Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 123 Depression - Pipeline by nLife Therapeutics, S.L., H2 2016 124 Depression - Pipeline by Novartis AG, H2 2016 125 Depression - Pipeline by Omeros Corporation, H2 2016 126 Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 127 Depression - Pipeline by Pfizer Inc., H2 2016 128 Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 129 Depression - Pipeline by Polleo Pharma Limited, H2 2016 130 Depression - Pipeline by Protagenic Therapeutics Inc., H2 2016 131 Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016 132 Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 133 Depression - Pipeline by Richter Gedeon Nyrt., H2 2016 134 Depression - Pipeline by Saniona AB, H2 2016 135 Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 136 Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 137 Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 138 Depression - Pipeline by Suven Life Sciences Ltd., H2 2016 139 Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 140 Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 141 Depression - Pipeline by Tetra Discovery Partners LLC, H2 2016 142 Depression - Pipeline by Trevena, Inc., H2 2016 143 Depression - Pipeline by TRImaran Pharma, Inc., H2 2016 144 Depression - Pipeline by Turing Pharmaceuticals AG , H2 2016 145 Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2016 146 Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016 147 Depression - Pipeline by Zogenix, Inc., H2 2016 148 Depression - Pipeline by Zysis Limited, H2 2016 149 Assessment by Monotherapy Products, H2 2016 150 Assessment by Combination Products, H2 2016 151 Number of Products by Stage and Target, H2 2016 153 Number of Products by Stage and Mechanism of Action, H2 2016 160 Number of Products by Stage and Route of Administration, H2 2016 167 Number of Products by Stage and Molecule Type, H2 2016 169 Depression - Dormant Projects, H2 2016 451 Depression - Dormant Projects (Contd..1), H2 2016 452 Depression - Dormant Projects (Contd..2), H2 2016 453 Depression - Dormant Projects (Contd..3), H2 2016 454 Depression - Dormant Projects (Contd..4), H2 2016 455 Depression - Dormant Projects (Contd..5), H2 2016 456 Depression - Dormant Projects (Contd..6), H2 2016 457 Depression - Dormant Projects (Contd..7), H2 2016 458 Depression - Dormant Projects (Contd..8), H2 2016 459 Depression - Dormant Projects (Contd..9), H2 2016 460 Depression - Dormant Projects (Contd..10), H2 2016 461 Depression - Dormant Projects (Contd..11), H2 2016 462 Depression - Dormant Projects (Contd..12), H2 2016 463 Depression - Dormant Projects (Contd..13), H2 2016 464 Depression - Dormant Projects (Contd..14), H2 2016 465 Depression - Dormant Projects (Contd..15), H2 2016 466 Depression - Dormant Projects (Contd..16), H2 2016 467 Depression - Dormant Projects (Contd..17), H2 2016 468 Depression - Dormant Projects (Contd..18), H2 2016 469 Depression - Dormant Projects (Contd..19), H2 2016 470 Depression - Dormant Projects (Contd..20), H2 2016 471 Depression - Dormant Projects (Contd..21), H2 2016 472 Depression - Dormant Projects (Contd..22), H2 2016 473 Depression - Dormant Projects (Contd..23), H2 2016 474 Depression - Dormant Projects (Contd..24), H2 2016 475 Depression - Discontinued Products, H2 2016 476 Depression - Discontinued Products (Contd..1), H2 2016 477 Depression - Discontinued Products (Contd..2), H2 2016 478 Depression - Discontinued Products (Contd..3), H2 2016 479 Depression - Discontinued Products (Contd..4), H2 2016 480 Depression - Discontinued Products (Contd..5), H2 2016 481 Depression - Discontinued Products (Contd..6), H2 2016 482 Depression - Discontinued Products (Contd..7), H2 2016 483
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
